Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
CA Stock MarketDetailed Quotes
Vaxil Bio Ltd (VXL)
- 0.280
- 0.0000.00%
15min DelayMarket Closed Apr 29 16:00 ET
767.08KMarket Cap-31.11P/E (TTM)
0.000High0.000Low0Volume0.000Open0.280Prev Close0.00Turnover0.32552wk High0.00%Turnover Ratio2.74MShares0.13052wk Low-0.009EPS TTM767.08KFloat Cap196.000Historical HighLossP/E (Static)2.74MShs Float0.130Historical Low-0.05EPS LYR0.00%Range %--Dividend TTM1.15P/B1Lot Size--Div Yield TTM
Vaxil Bio Ltd (VXL) Cash Flow
Quarterly+Annual
YOY
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 34.88%-28K | 22.39%-52K | -135.00%-47K | 57.22%-240K | -59.42%-110K | 12.24%-43K | 75.99%-67K | 87.80%-20K | 23.57%-561K | 62.30%-69K |
| Net income from continuing operations | 44.44%-20K | 222.22%44K | -20.69%-70K | 29.92%-178K | -284.62%-48K | -28.57%-36K | 71.65%-36K | 53.60%-58K | 56.51%-254K | 115.03%26K |
| Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Remuneration paid in stock | --0 | --0 | --0 | -75.00%5K | --0 | --0 | 0.00%2K | -25.00%3K | 17.65%20K | 20.00%6K |
| Other non cashItems | ---12K | ---73K | ---4K | ---18K | ---10K | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | 300.00%4K | 30.30%-23K | -22.86%27K | 85.02%-49K | 48.51%-52K | 103.45%1K | 78.57%-33K | 181.40%35K | -93.49%-327K | -573.33%-101K |
| -Change in receivables | 275.00%7K | 163.64%7K | -84.00%4K | 371.43%19K | 125.00%9K | -125.00%-4K | 71.05%-11K | 127.27%25K | -163.64%-7K | -20.00%4K |
| -Change in payables and accrued expense | -160.00%-3K | -36.36%-30K | 130.00%23K | 78.75%-68K | 41.90%-61K | 111.11%5K | 81.03%-22K | 118.52%10K | -77.78%-320K | -425.00%-105K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 34.88%-28K | 22.39%-52K | -135.00%-47K | 57.22%-240K | -59.42%-110K | 12.24%-43K | 75.99%-67K | 87.80%-20K | 23.57%-561K | 62.30%-69K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 127K | -250K | 0 | 0 | 0 | 0 | ||||
| Net other investing changes | ---- | ---- | ---- | ---250K | --0 | --0 | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --127K | ---- | ---- | ---250K | --0 | --0 | ---- | ---- | --0 | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | ||||||||||
| Cash from discontinued financing activities | ||||||||||
| Net cash flow | ||||||||||
| Beginning cash position | -41.09%347K | -56.20%403K | -52.24%448K | -37.88%938K | -46.98%535K | -44.64%589K | -31.45%920K | -37.88%938K | -32.62%1.51M | -40.12%1.01M |
| Current changes in cash | 276.79%99K | 83.64%-54K | -135.00%-47K | 12.66%-490K | -21.74%-84K | -14.29%-56K | -18.28%-330K | 87.80%-20K | 23.57%-561K | 62.30%-69K |
| Effect of exchange rate changes | -50.00%1K | -100.00%-2K | 0.00%2K | --0 | -50.00%-3K | 133.33%2K | -200.00%-1K | 150.00%2K | -466.67%-11K | -125.00%-2K |
| End cash Position | -16.45%447K | -41.09%347K | -56.20%403K | -52.24%448K | -52.24%448K | -46.98%535K | -44.64%589K | -31.45%920K | -37.88%938K | -37.88%938K |
| Free cash from | 34.88%-28K | 22.39%-52K | -135.00%-47K | 57.22%-240K | -59.42%-110K | 12.24%-43K | 75.99%-67K | 87.80%-20K | 23.57%-561K | 62.30%-69K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On May 1, the more than two-month-long military conflict involving the US, Israel, and Iran will reach a legal milestone, potentially increa
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm